- Home
- QNRX vs SNPX Comparison
QNRX vs SNPX Comparison
Compare QNRX & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- SNPX
- Stock Information
- Founded
- QNRX 2018
- SNPX 2012
- Country
- QNRX United States
- SNPX United States
- Employees
- QNRX N/A
- SNPX N/A
- Industry
- QNRX Medical/Dental Instruments
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- QNRX Health Care
- SNPX Health Care
- Exchange
- QNRX Nasdaq
- SNPX Nasdaq
- Market Cap
- QNRX 3.3M
- SNPX 3.1M
- IPO Year
- QNRX N/A
- SNPX N/A
- Fundamental
- Price
- QNRX $9.60
- SNPX $4.64
- Analyst Decision
- QNRX
- SNPX Strong Buy
- Analyst Count
- QNRX 0
- SNPX 1
- Target Price
- QNRX N/A
- SNPX N/A
- AVG Volume (30 Days)
- QNRX 12.9K
- SNPX 2.7M
- Earning Date
- QNRX 08-07-2025
- SNPX 08-13-2025
- Dividend Yield
- QNRX N/A
- SNPX N/A
- EPS Growth
- QNRX N/A
- SNPX N/A
- EPS
- QNRX N/A
- SNPX N/A
- Revenue
- QNRX N/A
- SNPX N/A
- Revenue This Year
- QNRX N/A
- SNPX N/A
- Revenue Next Year
- QNRX N/A
- SNPX N/A
- P/E Ratio
- QNRX N/A
- SNPX N/A
- Revenue Growth
- QNRX N/A
- SNPX N/A
- 52 Week Low
- QNRX $5.01
- SNPX $1.84
- 52 Week High
- QNRX $54.95
- SNPX $6.19
- Technical
- Relative Strength Index (RSI)
- QNRX 64.78
- SNPX 63.57
- Support Level
- QNRX $8.04
- SNPX $3.25
- Resistance Level
- QNRX $8.58
- SNPX $4.44
- Average True Range (ATR)
- QNRX 0.46
- SNPX 0.87
- MACD
- QNRX 0.04
- SNPX 0.04
- Stochastic Oscillator
- QNRX 98.57
- SNPX 80.22
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.